Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Wall St set for higher open after Micron revives AI optimism, upbeat economic data
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Lantern Pharma (LTRN) Reports Q2 Loss of $0.31
July 30, 2020 7:43 AM EDTLantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.31), versus ($0.32) reported last year.
"Lantern Pharma achieved important scientific and operational milestones during the quarter that have us well positioned for growth as we focus on being the leader in A.I.-enabled oncology drug development," said Panna Sharma, CEO and... More
